SANTA MONICA, Calif., Dec. 4, 2017 /PRNewswire/ -- Parallax Health Sciences, Inc. ("Parallax" or the "Company") (OTC-Pink: PRLX), and its wholly-owned subsidiaries Parallax Health Management, Inc. ("PHM"), Parallax Behavioral Health, Inc. ("PBH"), the owner of RoxSan Pharmacy, Inc. and emerging leader in Remote Patient monitoring technology, today announced that it has been granted Indian Patent No. 279743 stemming from its Indian Patent Application No. 785/MUMNP/2009 entitled "A Portable Apparatus for Improved Sample Analysis" filed October 25, 2007. The patent which covers discloses and claims the handheld TargetAnalyzer™ device, which is capable of housing and analyzing two assay cassettes. The claimed device optionally features wired or wireless data transfer and multiple data acquisition components including a keypad, a touch-pad, a barcode wand and / or a finger print reader. This patent expands Parallax's global ownership of the invention disclosed in its issued US Patent No.8,920,725. The same patented technology that enables Parallax's exclusive diagnostic platform has been issued in China as patent CNZ200780039901X. As well as in Hong Kong through Parallax's Application Serial No: 10103654.9, filed October 25, 2007 and issued as HK1137813, and a Macao Application No: MOJ/1298, that has been granted to the company as MOJ/001298, The invention has been continued in the U.S. through the issuance of a patent filed November 25, 2014 and issued as US Patent No.9,170,258. The entire portfolio remains open for continued filings both foreign and domestically.
"We are in a period of Intellectual Property assessment, expansion and acquisition at Parallax and the foresight of founders and their inventions are foundational and enabling in areas of human diagnostics and remote patient monitoring systems," stated Nathaniel Bradley, President of PHM. "Our ownership of foundational and International patent rights allows us to exclude others and create value for our stakeholders more rapidly and with greater uncontested scale. We are in the process of expanding our already extensive holdings through both strategic portfolio acquisitions and organic portfolio expansion."
Parallax Health Sciences reiterates its patent ownership and exclusive license right within the fields of human diagnostic testing, healthcare and remote patient care (RPC) as represented in its current and ongoing patent filing process and prosecution both in the United States and through applications made in countries that have both customer populations and Parallax business interests abroad.
Family #1 Portable Apparatus For Sample Analysis
United States Patents
CN Z200780039901.X Granted
HK 1137813 Granted
IN 785/MUMNP/2009 Granted
MO J/001298 – Granted
Family #2 Method to Identify Drugs, Moiety or Diagnostic
United States Patent
- 12/769,036 Pending
Family #3 Method to Produce a Plurality of Antibodies
United States Patent
- 13/253,366 Pending
Family #4 Method to Determine Immune Status
United States Patent
- 14/492,641 Pending
Family #5 Flow Thru Test w/ Pressure Indicator
United States Patent
- 14/786,272 Pending
Family #6 Remote User Monitoring – QOLPOM ACQUISITION
United States Patents
- 14/979,889 Pending
- 14/979,742 Pending
Family #7 PLATFORM FOR OPTIMIZING DATA DRIVEN OUTCOMES – ProEventa Acquisition
- U.S. Patent Application No. 14/212,429 Pending
- Related International filings, Pending
Additional filed applications being prosecuted and available for continuation and divisional filings:
- US13/253,366 - Title: "Method of Producing a Plurality of Isolated Antibodies to a Plurality of Cognate Antigens"
- US12/769,036 Title: "Method of Identifying Drugs, Targeting Moieties or -Diagnostics"
- US14/492,641 Title: "Method for Determining the Immune Status of a Subject"
- 14/786,272 Title: Flow Through Testing System with Pressure Indicator
About Parallax Health Sciences, Inc.
Parallax Health Sciences, Inc. (PRLX), headquartered in Santa Monica, CA, is a fully reporting Nevada corporation. The Company is focused on personalized patient healthcare through its established Pharmacy and Infertility businesses, and through Parallax Health Management, Parallax Behavioral Health and Parallax Diagnostics. For additional information, please visit www.parallaxhealthsciences.com.
About Parallax Health Management, Inc.
Parallax Health Management's (PHM) QOLPOM Hub – Establishing PHM user accounts directly with patients, doctors, hospitals, treatment centers, rehab centers and tele-health operations with seamless systems integration capabilities, technologies and know how. We utilize our award winning and patented QOLPOM Hub to deliver a continually improving and live customer experience. Parallax is the sole source of valuable remote patient monitoring systems and services that enable measurement of outcomes and the maximization of quality of life for end-users and peace of mind for those who love and care for them. Please visit http://parallaxhealthmanagement.com
About Parallax Behavioral Health, Inc.
Parallax Behavioral Health is a wholly owned subsidiary of Parallax Health Sciences, Inc. ("PARALLAX") that includes RoxSan Pharmacy, Inc. a Beverly Hills, CA based Compound and Fertility Specialty Pharmacy licensed in 37 States in the continental US; Parallax Diagnostics, Inc. a Santa Monica, CA based point of care diagnostic business and Parallax Health Management, Inc., a technology systems integrations company and home health hub with a first of its kind patented technology to support remote patient monitoring, medication adherence and tele-medicine.
Parallax Behavioral Health is the newest subsidiary within the Parallax Health Sciences portfolio and is a critical business unit to its overarching comprehensive healthcare strategy.
With its patent pending technology (R.E.B.O.O.T), which encompasses predictive, progressive behavior analytics and goal optimization software, and its Mobile App series, PBH is strategically positioned to enable large healthcare corporations to individuals take control of their health outcomes.
Health Organizations for the first time will have the opportunity to "scale" their patient adherence programs while having visibility into its effectiveness and bottom line impact.
Individual users will have a goal wizard, virtual coach and rules engine that will help create a personal path toward wellness. With personalized analysis, decision support and "goal" mastery feedback, the individual will be primed, guided and motivated to adhere to their treatment plan. Please visit http://www.parallaxhealth.net
About RoxSan Pharmacy, Inc.
RoxSan Pharmacy, Inc., a wholly owned subsidiary of Parallax Health Sciences, Inc., is a 63-year-old California-based Pharmacy that specializes in the compounding and fulfillment of prescriptions and infertility treatments. RoxSan Pharmacy is licensed in 42 States in the US. Please visit http://www.roxsan.com
About Parallax Diagnostics, Inc. ("Parallax Behavior")
Parallax Diagnostics is a wholly owned subsidiary of Parallax Health Sciences, which has an exclusive license, in perpetuity, to a line of proprietary, FDA approved, Point of Care single platform diagnostic tests focusing on the detection and monitoring of infectious diseases. Please visit http://www.parallaxdiagnostics.com
This release includes forward-looking statements contained within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Parallax's expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions, are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Parallax's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in Parallax's Form 10-K and other report filings with the SEC. Parallax is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Parallax Health Sciences, Inc.